Literature DB >> 7887157

The shape of the corneal apical zone after excimer photorefractive keratectomy.

S Patel1, J Marshall, F W Fitzke, D S Gartry.   

Abstract

Applying an experimental photo-keratoscope, which assesses the shape of cornea within the pupillary region, to a group of subjects who have undergone excimer laser photorefractive keratectomy over a central 4 mm chord diameter of the cornea, we report the shape of the typical cornea within the ablated zone conforms to a steepening ellipse (average shape factor, 1.25). A statistically significant difference in the mean shape factor (asphericity) between the photoablated and the normal cornea (average shape factor 0.89) was not confirmed. However, there is more variability in the shape factors found in the photorefractive keratectomy group compared with normals, within the same distance from the corneal apex. Using the criterion of overlap within two standard deviations, averaging the vertical horizontal meridians, 75% of photorefractive keratectomy eyes fall within the shape factor limits of the normal eye group. In all cases the post-ablated corneal surface was found to be regular in terms of surface quality alone. The excimer photorefractive keratectomy technique is therefore a clinically acceptable method of refractive surgery.

Entities:  

Mesh:

Year:  1994        PMID: 7887157     DOI: 10.1111/j.1755-3768.1994.tb07184.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  2 in total

1.  Relationship between anterior corneal asphericity and refractive variables.

Authors:  Amelia Nieto-Bona; Amalia Lorente-Velázquez; Robert Mòntes-Micó
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-02       Impact factor: 3.117

2.  Contralateral Eye Study of Topography Guided versus Q Value Adjusted Photorefractive Keratectomy in Myopia and Myopic Astigmatism.

Authors:  Rania E Gad; Mohamed Hosny; Rania A Ahmed; Ahmed M Sherif; Yehia Salah Eldin
Journal:  Clin Ophthalmol       Date:  2021-04-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.